Boehringer Ingelheim completes deal on Fort Dodge acquisition

Boehringer Ingelheim Animal Health has closed the deal to acquire a significant portion of the Fort Dodge Animal Health business from Pfizer.

Boehringer Ingelheim, a global pharmaceutical group of companies, together with its US animal health business, Boehringer Ingelheim Vetmedica, Inc., has announced that it has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business.

The acquisition, which includes products in the US, Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthens the company's position as a leading vaccine supplier.

As part of the deal, Boehringer Ingelheim will acquire the Duramune® line of vaccines for dogs, the Fel-O-Vax® line of vaccines for cats, and the Rabvac® line of rabies vaccines manufactured and sold in the US, Canada and Australia. In addition, a portfolio of pet and equine pharmaceutical products currently sold in the US is also included in the deal.

The company will also acquire cattle vaccines in the US and Canada including the Triangle®, Pyramid®, and Presponse® vaccine lines. Pharmaceutical products being acquired include Cydectin® (moxidectin) for cattle and sheep as well as Polyflex® (ampicillin sodium).

The dairy portfolio includes the key brands Today® and Tomorrow®. Several Canadian swine vaccines are included in the acquisition as are some cattle vaccines sold in Europe and South Africa.